New Projects information at Drug Development Technology New and updated information from Projects listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Projects information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer i… Wed, 15 Mar 2017 14:04:00 GMT Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. Thu, 09 Mar 2017 00:00:00 GMT Alecensa (alectinib) for Treatment of ALK-positive Non-small Cell Lung Cancer http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alecensa-alectinib-for-treatment-of-alk-positive-non-small-cell-lung-cancer-nsclc/ Alecensa (alectinib) is a kinase inhibitor intended for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Thu, 02 Mar 2017 11:47:00 GMT Emflaza (deflazacort) for the Treatment of Duchenne Muscular Dystrophy http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ http://www.drugdevelopment-technology.com/projects/emflaza-deflazacort-for-the-treatment-of-duchenne-muscular-dystrophy/ Emflaza™ (deflazacort) is the first glucocorticoid drug approved in the US for the treatment of patients aged five and older suffering from duchenne muscular dystrophy (DMD). The drug was discovered and developed by Marathon Pharmaceuticals. Fri, 17 Feb 2017 00:00:00 GMT Symbicort (budesonide and formoterol) for the Treatment of Asthma http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ http://www.drugdevelopment-technology.com/projects/symbicort-budesonide-and-formoterol-for-the-treatment-of-asthma/ Symbicort (budesonide and formoterol) is an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) indicated for the treatment of asthma in paediatric patients aged between six and 12 years. The drug was discovered and developed by AstraZe… Fri, 17 Feb 2017 00:00:00 GMT Trulance™ (Plecanatide) for the Treatment of Adults with Chronic Idiopathic Constipation (CIC) http://www.drugdevelopment-technology.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/ http://www.drugdevelopment-technology.com/projects/trulance-plecanatide-for-the-treatment-of-adults-with-chronic-idiopathic-constipation-cic/ Trulance™ (Plecanatide) is a guanylate cyclase-C (GC-C) agonist indicated for the treatment of adult patients with chronic idiopathic constipation (CIC). Mon, 06 Feb 2017 00:00:00 GMT Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma http://www.drugdevelopment-technology.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/ http://www.drugdevelopment-technology.com/projects/avelumab-for-the-treatment-of-metastatic-merkel-cell-carcinoma/ Avelumab (formerly MSB0010718C) is a human PD-L1 monoclonal antibody being investigated for the treatment of metastatic Merkel cell carcinoma (MCC). Mon, 30 Jan 2017 00:00:00 GMT Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) http://www.drugdevelopment-technology.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/ http://www.drugdevelopment-technology.com/projects/spinraza-nusinersen-for-the-treatment-of-spinal-muscular-atrophy-sma/ Spinraza™ (nusinersen) is an anti-sense oligonucleotide indicated for treatment of spinal muscular atrophy (SMA) in paediatric and adult patients. Fri, 27 Jan 2017 00:00:00 GMT Rubraca (rucaparib) for the Treatment of Advanced Ovarian Cancer http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/rubraca-rucaparib-for-the-treatment-of-advanced-ovarian-cancer/ Poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor Rubraca™ (rucaparib) is indicated for the treatment of BRCA mutation-linked advanced ovarian cancer. Thu, 19 Jan 2017 00:00:00 GMT Soliqua 100/33 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/soliqua-10033-for-the-treatment-of-type-2-diabetes/ Developed by Sanofi, Soliqua 100/33 (insulin glargine & Lixisenatide injection) is indicated for the treatment of Type 2 diabetes. Mon, 19 Dec 2016 00:00:00 GMT Xultophy 100/3.6 for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/xultophy-10036-for-the-treatment-of-type-2-diabetes/ Developed by Novo Nordisk, Xultophy 100/3.6 is indicated for the treatment of type 2 diabetes. Thu, 01 Dec 2016 00:00:00 GMT Stelara (Ustekinumab) for the Treatment of Moderate to Severe Crohn’s Disease http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ http://www.drugdevelopment-technology.com/projects/stelara-ustekinumab-for-the-treatment-of-moderate-to-severe-crohns-disease/ Developed by Janssen Biotech, Stelara (Ustekinumab) is indicated for the treatment of moderate to severely active Crohn's disease. Tue, 29 Nov 2016 00:00:00 GMT Vemlidy (Tenofovir Alafenamide) for Treatment of Chronic Hepatitis B Virus Infection http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ http://www.drugdevelopment-technology.com/projects/vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection/ Developed by Gilead Sciences, Vemlidy (Tenofovir Alafenamide) is indicated for the treatment of Hepatitis B virus infection with compensated liver disease in adult patients. Thu, 24 Nov 2016 00:00:00 GMT Zinplava (bezlotoxumab) for the Treatment of Clostridium Difficile Infection http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ http://www.drugdevelopment-technology.com/projects/zinplava-bezlotoxumab-for-the-treatment-of-clostridium-difficile-infection/ Zinplava (bezlotoxumab) is an injectable solution developed by Merck indicated for the treatment of clostridium difficile infection (CDI) in adult patients who are already receiving anti-bacterial drug treatment. Tue, 22 Nov 2016 00:00:00 GMT Invokamet XR for the Treatment of Type 2 Diabetes in Adults http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ http://www.drugdevelopment-technology.com/projects/invokamet-xr-for-the-treatment-of-type-2-diabetes-in-adults/ Developed by Janssen Pharmaceuticals, Invokamet XR (Canagliflozin / Metformin Hydrochloride Extended Release) is indicated for the treatment of Type 2 diabetes in adults. Thu, 17 Nov 2016 00:00:00 GMT Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma in adult patients. Thu, 27 Oct 2016 23:00:00 GMT Exondys 51 (eteplirsen) for the Treatment of Duchenne Muscular Dystrophy (DMD) http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ http://www.drugdevelopment-technology.com/projects/exondys-51-eteplirsen-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ Exondys 51 (eteplirsen) is an injectable solution developed by Sarepta Therapeutics. Thu, 20 Oct 2016 23:00:00 GMT Carnexiv (carbamazepine) for the Treatment of Partial, Generalised Tonic-clonic Seizures in Adults http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ http://www.drugdevelopment-technology.com/projects/carnexiv-carbamazepine-for-the-treatment-of-certain-seizure-types-in-adults/ Carnexiv (carbamazepine) is an injectable formulation developed by Lundbeck for partial, generalised tonic-clonic seizures in adult patients who are unable to temporarily take oral medication. Thu, 13 Oct 2016 23:00:00 GMT Dupixent (dupilumab) for the Treatment of Atopic Dermatitis http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ http://www.drugdevelopment-technology.com/projects/dupixent-dupilumab-for-the-treatment-of-atopic-dermatitis/ Dupixent (dupilumab) is an investigational drug being developed by Sanofi and Regeneron as a treatment for moderate to severe atopic dermatitis in adult patients. Wed, 12 Oct 2016 23:00:00 GMT Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ http://www.drugdevelopment-technology.com/projects/ocrevus-ocrelizumab-for-the-treatment-of-multiple-sclerosis/ Ocrevus (ocrelizumab), developed by Genentech, a member of Roche Group, is indicated for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis. Thu, 06 Oct 2016 23:00:00 GMT